Project Grant R21CA312456
Award Date 6/17/26
Completion Date 5/31/28
Dollars Obligated $385K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $621,574 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This five-year research initiative investigates the regulatory mechanisms of AMP-activated protein kinase (AMPK) in tumor-associated macrophages (TAMs) to develop novel strategies for enhancing cancer immunotherapy efficacy. The research addresses a critical gap in...
- Federal Grant Award Summary The National Cancer Institute awarded The Ohio State University a Project Grant of $394,695 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on June 17, 2026, with a completion date of May 31, 2028. This award supports development and validation of computational approaches to identify and characterize tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in breast cancer tissue samples. The project aims to overcome...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a Project Grant totaling $192,564 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports the development of chimeric antigen receptor (CAR) modified natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The research aims to advance NK cell engineering as a safer and more effective...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $449,222 Project Grant effective August 20, 2025, through July 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the cellular and molecular mechanisms by which PD-1H (Programmed Death-1 Homolog, also known as VISTA) mediates immune suppression in acute myeloid leukemia (AML) and to evaluate its potential as a therapeutic target. The...
- Federal Grant Award Summary The Ohio State University received a $390,906 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2027. This research initiative, titled "Decoding Dural Nociceptors as Drivers of Immune Suppression in Glioblastoma," investigates the role of pain-sensing sensory neurons (nociceptors) in regulating the immunosuppressive tumor microenvironment...
- Federal Grant Award Summary The Ohio State University received a $1,574,999 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on June 15, 2025, with a completion date of June 14, 2028. The project, titled "SLIT2 as a Novel Approach for Targeting Metastatic Breast Cancer," is conducted through the university's Office of Sponsored Programs in Columbus, Ohio. This award supports advanced biomedical research aimed...
- Federal Grant Award Summary Case Western Reserve University received a $630,108 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 13, 2026, with completion targeted for February 28, 2030. The award funds research into theranostic approaches for breast cancer treatment utilizing a novel compound designated AKRO-6QC, which functions as both a targeted fluorescence imaging agent for image-guided...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Ohio State University a Project Grant of $157,500 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 15, 2025, with completion scheduled for June 30, 2027. This award supports research investigating the roles of the TIP60 chromatin remodeling complex in DNA double-strand break (DSB) repair mechanisms. The research focuses on understanding how the TIP60 complex, particularly through its KAT5...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University $463,692 under the Cancer Biology Research program (CFDA 93.396) for a five-year project (June 1, 2026 – May 31, 2031) focused on comprehensive structural and dynamic characterization of human K-RAS oncoprotein. The project delivers fundamental research services aimed at understanding K-RAS interactions with binding partners and small-molecule ligands in both normal and oncogenic mutant...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Ohio State University a $188,351 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on September 3, 2025, with a completion date of August 31, 2028. This award supports research and career development activities focused on mutation-specific pan-KRAS (Kirsten rat sarcoma viral oncogene homolog) inhibitor signaling responses and anti-tumor effects. The project involves comprehensive genetic,...